Vivo Capital, LLC
Sector Allocation
- Healthcare98.3%$1.1B
- Other1.6%$18.1M
AUM History
13fpro.ai/research/fund/vivo-capital-llc-1674712
Conviction and streaks
Diversifying · top 10 = 52.4%From the fund's last 12 quarters of 13F filings: positions held longest at size, and names it added to or trimmed several quarters running.
Largest positions — Q2 2026
TRVI
$95.0MPRAX
$90.8MERAS
$75.6MAVBP
$58.4MABVX
$55.3MTNGX
$43.1MCRVS
$41.9MDRUG
$39.1MSVA
$38.2MTENX
$36.4MACRS
$35.4MDYN
$34.6MDNTH
$34.5MANRO
$31.9MDBVT
$30.3MSABS
$28.5MMLTX
$27.3MLBRX
$26.0MNERV
$24.0MDSGN
$23.3M
Top 20 stock positions. Options are left out: 13F reports them at the underlying's value.
13fpro.ai/research/fund/vivo-capital-llc-1674712
Vivo Capital, LLC 13F holdings — Q2 2026
$1.1B portfolio (-8.6% QoQ) · 47 holdings · Q2 2026 13F · top 10 are 52% of the stock portfolio
$95.0M
8.7% of stocks
No changeThis quarter-27.7%Since filed5+ qtrsHeld$90.8M
8.3% of stocks
-20%This quarter-27.1%Since filed5+ qtrsHeld$75.6M
6.9% of stocks
-66%This quarter-17.2%Since filed5+ qtrsHeld$58.4M
5.3% of stocks
+90%This quarter-47.8%Since filed2 qtrsHeld$55.3M
5.0% of stocks
+73%This quarter-26.9%Since filed4 qtrsHeld$43.1M
3.9% of stocks
-36%This quarter-10.6%Since filed5+ qtrsHeld$41.9M
3.8% of stocks
No changeThis quarter-29.2%Since filed5+ qtrsHeld$39.1M
3.6% of stocks
No changeThis quarter-29.3%Since filed5+ qtrsHeld$38.2M
3.5% of stocks
No changeThis quarter—Since filed5+ qtrsHeld$36.4M
3.3% of stocks
+1100%This quarter-4.4%Since filed5+ qtrsHeld
All holdings — Vivo Capital, LLC (Q2 2026)
47 disclosed positions from the Form 13F-HR on SEC EDGAR, with quarter-over-quarter share changes. Largest by value first; the ten above are not repeated.
| # | Company | Held | Source | |||||||
|---|---|---|---|---|---|---|---|---|---|---|
| 11 | Aclaris Therapeutics, Inc. | Healthcare | $35.4M | 3.2% | 6.69M | +0.4% | 5+ qtrs | AI quality score is Pro: unlock with a free trial | 13F | |
| 12 | Dyne Therapeutics, Inc. | Healthcare | $34.6M | 3.2% | 1.56M | — | 5+ qtrs | AI quality score is Pro: unlock with a free trial | 13F | |
| 13 | Dianthus Therapeutics, Inc. /DE/ | Healthcare | $34.5M | 3.1% | 354K | — | 4 qtrs | AI quality score is Pro: unlock with a free trial | 13F | |
| 14 | Alto Neuroscience, Inc. | Healthcare | $31.9M | 2.9% | 1.21M | +17% | 3 qtrs | AI quality score is Pro: unlock with a free trial | 13F | |
| 15 | DBV Technologies S.A.adr | Healthcare | $30.3M | 2.8% | 1.84M | -31% | 5+ qtrs | AI quality score is Pro: unlock with a free trial | 13F | |
| 16 | SAB Biotherapeutics, Inc. | Healthcare | $28.5M | 2.6% | 7.30M | -36% | 4 qtrs | AI quality score is Pro: unlock with a free trial | 13F | |
| 17 | MoonLake Immunotherapeutics | Healthcare | $27.3M | 2.5% | 1.40M | +40% | 3 qtrs | AI quality score is Pro: unlock with a free trial | 13F | |
| 18 | LB PHARMACEUTICALS INC | Healthcare | $26.0M | 2.4% | 800K | — | 4 qtrs | AI quality score is Pro: unlock with a free trial | 13F | |
| 19 | Minerva Neurosciences, Inc. | Healthcare | $24.0M | 2.2% | 4.32M | — | 3 qtrs | AI quality score is Pro: unlock with a free trial | 13F | |
| 20 | Design Therapeutics, Inc. | Healthcare | $23.3M | 2.1% | 1.61M | — | 3 qtrs | AI quality score is Pro: unlock with a free trial | 13F | |
| 21 | Oric Pharmaceuticals, Inc. | Healthcare | $20.0M | 1.8% | 1.85M | — | 5+ qtrs | AI quality score is Pro: unlock with a free trial | 13F | |
| 22 | Camp4 Therapeutics Corp | Healthcare | $18.6M | 1.7% | 4.25M | — | 4 qtrs | AI quality score is Pro: unlock with a free trial | 13F | |
| 23 | — | Faeth Therapeutics Inc - Common | — | $18.1M | 1.6% | 722K | — | — | — | 13F |
| 24 | ACHIEVE LIFE SCIENCES, INC. | Healthcare | $18.0M | 1.6% | 2.75M | New | 1 qtr | AI quality score is Pro: unlock with a free trial | 13F | |
| 25 | Compass Therapeutics, Inc. | Healthcare | $17.0M | 1.6% | 7.76M | -19% | 5+ qtrs | AI quality score is Pro: unlock with a free trial | 13F | |
| 26 | $ANTX | AN2 Therapeutics, Inc. | Healthcare | $15.3M | 1.4% | 3.15M | — | |||
| 27 | $EDIT | Editas Medicine, Inc. | Healthcare | $11.5M | 1.1% | 3.56M | New | |||
| 28 | $GERN | GERON CORP | Healthcare | $11.1M | 1.0% | 8.67M | — | |||
| 29 | $ODTX | Odyssey Therapeutics, Inc. | Healthcare | $10.8M | 1.0% | 575K | New | |||
| 30 | $EPRX | EUPRAXIA PHARMACEUTICALS INC. | Healthcare | $8.9M | 0.8% | 1.35M | — | |||
| 31 | $OKUR | OnKure Therapeutics, Inc. | Healthcare | $8.8M | 0.8% | 1.93M | — | |||
| 32 | $OLMA | Olema Pharmaceuticals, Inc. | Healthcare | $8.4M | 0.8% | 672K | — | |||
| 33 | $MNPR | Monopar Therapeutics | Healthcare | $8.4M | 0.8% | 91K | — | |||
| 34 | $AURA | Aura Biosciences, Inc. | Healthcare | $8.3M | 0.8% | 1.17M | New | |||
| 35 | $SRZN | Surrozen, Inc./DE | Healthcare | $6.7M | 0.6% | 260K | — | |||
| 36 | $ALXO | ALX ONCOLOGY HOLDINGS INC | Healthcare | $6.6M | 0.6% | 3.18M | — | |||
| 37 | $MSLE | Satellos Bioscience Inc. | Healthcare | $6.3M | 0.6% | 814K | New | |||
| 38 | $AVTX | Avalo Therapeutics, Inc. | Healthcare | $5.1M | 0.5% | 275K | New | |||
| 39 | $PEPG | PepGen Inc. | Healthcare | $4.2M | 0.4% | 2.33M | — | |||
| 40 | $VALN | Valneva SE | Healthcare | $4.0M | 0.4% | 763K | New | |||
| 41 | $SERA | SERA PROGNOSTICS, INC. | Healthcare | $3.0M | 0.3% | 1.65M | — | |||
| 42 | $UNCY | Unicycive Therapeutics, Inc. | Healthcare | $2.6M | 0.2% | 550K | -69% | |||
| 43 | $TIL | Instil Bio, Inc. | Healthcare | $2.3M | 0.2% | 293K | — | |||
| 44 | $INM | InMed Pharmaceuticals Inc. | Healthcare | $1.2M | 0.1% | 798K | New | |||
| 45 | $BOLT | Bolt Biotherapeutics, Inc. | Healthcare | $279K | 0.0% | 72K | — | |||
| 46 | $KTTA | Pasithea Therapeutics Corp. | Healthcare | $240K | 0.0% | 465K | -78% | |||
| 47 | $DTIL | PRECISION BIOSCIENCES INC | Healthcare | $37K | 0.0% | 4,675 | — |
What changed in Q2 2026
Against the previous quarter's 13F: 8 new, 6 added to, 8 trimmed, 6 sold out. Share-count changes; largest moves by dollar size first.
New positions (8)
$ACHVACHIEVE LIFE SCIENCES, INC.$18.0M
first bought this quarter
$EDITEditas Medicine, Inc.$11.5M
first bought this quarter
$ODTXOdyssey Therapeutics, Inc.$10.8M
first bought this quarter
$AURAAura Biosciences, Inc.$8.3M
first bought this quarter
$MSLESatellos Bioscience Inc.$6.3M
first bought this quarter
$AVTXAvalo Therapeutics, Inc.$5.1M
first bought this quarter
+2 more in the Excel export
Added to (6)
now $36.4M · held 5+ qtrs
now $58.4M · held 2 qtrs, 2 adds in a row
now $55.3M · held 4 qtrs
now $27.3M · held 3 qtrs
now $31.9M · held 3 qtrs
now $35.4M · held 5+ qtrs
Trimmed (8)
now $75.6M · held 5+ qtrs
now $43.1M · held 5+ qtrs
now $90.8M · held 5+ qtrs
now $28.5M · held 4 qtrs
now $30.3M · held 5+ qtrs
$UNCYUnicycive Therapeutics, Inc.-69%
now $2.6M · held 5+ qtrs
+2 more in the Excel export
Holdings by quarter
Every 13F Vivo Capital, LLC has filed, 38 earlier quarters. Pick one to see what it held then.
Is it too late to follow Vivo Capital?
Q2 2026 13F filed with the SEC on Aug 14, 2026. Prices are closing prices as of Oct 27, 2026.
Average quality of Vivo Capital's top 20 holdings: 21/100 (our AI quality score, weighted by position size; 3 of the 20 are scored)
Top 10 since filing
-25.5%
Value-weighted move of the 10 largest stock positions
Turnover
14%
Last quarter; 50% over the last 4
Top 10 weight
52%
Share of the stock portfolio in its 10 largest positions
Held 4+ quarters
76%
Share of portfolio value in positions held a year or more
Highest-quality names it owns(among its 100 largest positions)
The 8 highest-scoring companies in this portfolio are a Pro feature.
How these are measured
- Moves since the quarter-end and since the filing date use our own daily closing prices, from the close on (or just before) each date to the latest close.
- Turnover is the lesser of shares bought or sold in a quarter, valued at the quarter-end prices in the 13F, divided by the average of the two quarters' stock portfolio values.
- Quarters held and add/trim streaks count back only through quarters whose filed holdings add up to the filing's own cover-page total (back to Q2 2025 for this fund). A change counts as an add or a trim when the split-adjusted share count moves by more than 1%.
- Estimate, not the fund's reported cost. For each quarter in the current holding period in which the fund's share count rose (split-adjusted), we take that quarter's average daily close and weight it by the shares added; sales do not change an average cost. Quarters where the stock's price history and the 13F's own implied price disagree by more than 2x are left out.
- Put and call option rows report the value of the underlying shares, not a position the fund paid for, so they are left out of all of the above.
Portfolio Overview
Vivo Capital, LLC disclosed 47 positions worth $1.1B in its Form 13F-HR for Q2 2026, led by $TRVI (Trevi Therapeutics, Inc.) at 8.7% of the equity portfolio, followed by $PRAX and $ERAS. During the quarter the fund opened 8 new positions and exited 6 — including a new stake in $ACHV and a full exit from $TERN. The portfolio is most concentrated in Healthcare (98.3% of disclosed assets). All figures are sourced directly from Vivo Capital, LLC’s Form 13F-HR filing with the SEC under CIK 1674712.
Funds like this
managers whose biggest positions overlap Vivo Capital'sBrowse Top Institutional Investors
13F Pro tracks 8,700+ institutional investors filing 13F reports with the SEC.
to search all 8,700+ institutional filers.
AI-Powered Hedge Fund Analysis: Vivo Capital, LLC
13F Pro is an AI hedge fund tracker and stock research platform. For Vivo Capital, LLC (SEC CIK: 1674712), the platform ingests every quarterly Form 13F filing and applies AI-powered analysis on top — 10 specialized AI analysts (value, growth, momentum, macro, activist, and more) debate the fund's top positions and publish AI-generated analysis with cited SEC sources.
Every holding in Vivo Capital, LLC's portfolio is scored on an AI quality ranking built from its SEC filings (ROIC, FCF margin, revenue growth, institutional flow, earnings quality, shareholder dilution, and more). Track accumulation and distribution quarter over quarter, identify conviction positions, and see AI stock analysis for each position — alongside 8,700+ other institutional filers and 2,800+ AI-ranked companies.